Secondary objectives
death, pneumothorax, ’ PMA➢, brain injury, patent ductus arteriosus, BPD
NECROTIZING ENTEROCOLITIS, BRONCHOPULMONARY DYSPLASIA (BPD), PNEUMOTHORAX, INTESTINAL PERFORATION, RETINOPATHY OF PREMATURITY
To determine whether intratracheal budesonide mixed with surfactant increases survival free of bronchopulmonary dysplasia (BPD) at 36 weeks’ postmenstrual age (PMA) in extremely preterm infants born before 28 weeks’ gestation.To determine whether intratracheal budesonide mixed with surfactant:
➢ Reduces BPD and/or BPD severity at 36 weeks’ PMA➢ Reduces death before 36 weeks’ PMA➢ Reduces death before hospital discharge➢ Reduces other major neonatal morbidities (e.g., brain injury, retinopathy of prematurity, necrotizing enterocolitis, spontaneous intestinal perforation, pneumothorax requiring drainage, treated patent ductus arteriosus)➢ Improves respiratory status at 40 weeks’ PMA➢ Reduces the duration of hospitalization, respiratory support, and supplemental oxygen therapy